Alzheimer’s disease
An investigational Alzheimer’s disease drug from Tetra Therapeutics appeared to improve language ability and learning in adults with Fragile X Syndrome, according to a new study reported in Nature Medicine.
Researchers from Albert Einstein’s College of Medicine are excited with the recently published findings of an experimental drug that reversed key symptoms of Alzheimer’s disease in mice.
The long and strange journey of Biogen’s Alzheimer’s drug aducanumab is coming to an end. Whether it will be a complete ending—with the U.S. FDA rejecting it—or a new chapter, with an approval, remains to be seen.
An optimistic trend reported from the experimental drug lecanemab (BAN2401) clinical trials broaches the question of when the joint asset of Eisai Co., Ltd. and Biogen Inc. will hit the market.
Three members of the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee published their objections to the drug in a JAMA article.
One of the big drugs investors, analysts and pretty much everyone else in the biopharma industry is keeping an eye on is Biogen and Eisai’s aducanumab for Alzheimer’s disease.
Study findings published in Alzheimer’s & Dementia: Translational Research and Clinical Interventions suggest Leukine® leads to significant reversal of cognitive impairment and normalizes blood-based biomarkers of dementia in patients with mild-to-moderate Alzheimer’s disease.
A new nonhuman primate Alzheimer’s disease model developed by researchers from University of California, Davis and elsewhere could open the door to getting better therapies into human testing.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
A drug to halt the progression of Alzheimer’s disease will likely be approved within the next three years, and Alzheon’s ALZ-801 might be the leading candidate.
PRESS RELEASES